Mentioned 11× · first seen 28-apr-2026 · last seen 13-sep-2026

Pre-transplant bridging (ruxolitinib)

Current understanding

To be populated as evidence accumulates.

Evidence log

2026-07-20 — Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis: Phase II trial (trial-early) in reduced-intensity haploidentical HCT for primary/secondary MF: pre-transplant JAK inhibitor bridging yielded universal engraftment with no graft failure, but substantial GVHD — supports engraftment safety of pre-transplant ruxolitinib in the haplo-RIC setting while highlighting GVHD as the residual limitation driving expansion into a peri-transplant dosing cohort. (novelty: 3)
2026-08-23 — Sequential High-Dose Ruxolitinib and Low-Dose Splenic Irradiation for Pretransplant Management of Splenomegaly Before Allogeneic Hematopoietic Cell Transplantation With Fludarabine/Busulfan-Based Conditioning in Myelofibrosis.: Retrospective series (observational): sequential high-dose ruxolitinib followed by low-dose splenic irradiation produced stepwise pretransplant spleen reduction with encouraging engraftment and early survival on a Flu/Bu conditioning backbone, extending pre-transplant ruxolitinib bridging into a combined pharmacologic + radiotherapeutic debulking sequence. (novelty: 3)
2026-04-03 — Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation: Trial-early: a randomized FluBu vs. FluBu+low-dose TBI conditioning trial for myeloid malignancies (including MPNs) provides context for the conditioning backbone onto which pre-transplant ruxolitinib bridging is layered. (novelty: 3)
2026-02-19 — Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: Phase II trial of peri-transplant ruxolitinib (before/during/after HCT) on a tacrolimus/methotrexate backbone in older MF and MDS/MPN overlap patients further broadens the pre-transplant bridging paradigm into a continuous peri-transplant exposure window in an older, comorbid population (trial-early). (novelty: 3)
2026-03-31 — Momelotinib During and After HCT in Myelofibrosis: Trial-early: a phase I study of momelotinib during/after HCT extends the peri-transplant JAK-inhibitor paradigm beyond ruxolitinib and gecacitinib, adding a JAK1/2+ACVR1 inhibitor (with hepcidin-suppressive anemia benefit) as a candidate peri-transplant agent. (novelty: 3)
2026-03-13 — Gecacitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis: cross-connection with gecacitinib-jak-acvr1-inhibitor: Gecacitinib peri-transplant protocol parallels the ruxolitinib pre-transplant bridging paradigm, extending JAK inhibition across all three transplant phases. (novelty: 3)
2026-04-14 — Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis: cross-connection with peritransplant-ruxolitinib-gvhd: Peri-transplant protocol extends pre-transplant bridging ruxolitinib by continuing the drug during and after HSCT, building on the same anti-inflammatory rationale. (novelty: 3)
2026-03-30 — Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation: Itacitinib + tacrolimus + sirolimus phase IIa trial for GVHD prophylaxis in RIC allo-SCT (including MF) further broadens the peri-transplant JAK-inhibitor toolkit beyond ruxolitinib bridging, joining gecacitinib as alternative selective JAK-inhibitor strategies in the transplant setting (trial-early). (novelty: 3)
2026-03-11 — High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly: Trial-early: high-dose ruxolitinib combined with busulfan tested as pre-transplant conditioning (not just bridging) in MF patients with splenomegaly, aiming to debulk spleen and improve allo-SCT outcomes — expands the pre-transplant ruxolitinib paradigm into intensified conditioning dosing. (novelty: 3)
2026-02-27 — Efficacy and Safety of Gecacitinib Hydrochloride in Prophylaxis Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis: Gecacitinib (a novel JAK/ACVR1 inhibitor) is emerging as an alternative JAK-inhibitor candidate in the peri-transplant period for MF, being tested with ATG for aGVHD prophylaxis rather than as bridging — broadens the JAK-inhibitor toolkit around allo-HSCT (trial-early). (novelty: 4)